MedImmune buys into Infinity's pipeline

Infinity Pharmaceuticals has inked a big development pact with MedImmune to advance new therapies for blood-related cancers and solid tumors. Infinity nets $70 million up front and up to $430 million in scheduled milestones. The two companies will also share all costs and profits. IPI-504, the most advanced of the drug candidates involved in the deal, targets Heat Shock Protein 90 (Hsp90) and the Hedgehog cell-signaling pathway.

"Hsp90 and Hedgehog are among the most attractive targeted therapy opportunities in cancer research today, and the Infinity programs have a very strong competitive position," said Edward T. Mathers, MedImmune's executive vice president, corporate development and venture. "With IPI-504, we have a promising drug candidate with already-established preclinical in vivo proof of concept and the potential to reach the market by 2010."

- see the release on the licensing deal

Suggested Articles

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"